Rohto Seiyaku KK header image

Rohto Seiyaku KK

4527

Equity

ISIN JP3982400008 / Valor 763212

Tokyo Stock Exchange (2024-09-18)
JPY 3,482.00-2.16%

Rohto Seiyaku KK
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Rohto Seiyaku KK, also known as Rohto Pharmaceutical Co., Ltd., is a Japanese company engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company focuses on creating innovative solutions for various health issues, including urinary incontinence. Rohto's product portfolio spans over-the-counter medications, skincare products, and eye care solutions, catering to both domestic and international markets. With a commitment to advancing healthcare, Rohto continually invests in research and development to introduce new values, products, and business ventures within the healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.08.2024):

Revenue Growth

Rohto Seiyaku KK reported a significant increase in net sales for the first quarter of the fiscal year ending March 31, 2025. The company achieved net sales of ¥68,356 million, up from ¥61,171 million in the same period the previous year. This growth was driven by the recovery in economic activity, increased inbound demand, and favorable product proposals.

Operating Income

Despite a rise in the cost of sales ratio, Rohto Seiyaku KK managed to increase its operating income to ¥11,790 million in the first quarter of FY3/2025, compared to ¥11,292 million in the same quarter of the previous year. This was achieved through effective utilization of selling, general, and administrative expenses.

Profit Decline

Rohto Seiyaku KK experienced a decrease in profit attributable to owners of the parent, which fell to ¥8,482 million in the first quarter of FY3/2025 from ¥9,090 million in the same period the previous year. The decline was primarily due to extraordinary losses despite the increase in net sales and operating income.

Segment Performance in Asia

In the Asian market, Rohto Seiyaku KK saw a significant increase in both sales and profits. Sales in Asia reached ¥18,091 million, up 13.8% year-over-year, while operating profit surged by 51.2% to ¥4,320 million. This growth was attributed to strong sales in Indonesia, Hong Kong, Taiwan, and a recovery in China and Vietnam.

Dividend Increase

Rohto Seiyaku KK announced an increase in its annual dividend from 30 yen to 33 yen, reflecting the company's strong financial performance and commitment to returning value to its shareholders. This decision was made in light of the positive outlook for the fiscal year ending March 31, 2025.

Summarized from source with an LLMView Source

Key figures

-14.2%1Y
94.3%3Y
141%5Y

Performance

34.5%1Y
32.2%3Y
30.3%5Y

Volatility

Market cap

5824 M

Market cap (USD)

Daily traded volume (Shares)

549,400

Daily traded volume (Shares)

1 day high/low

3606 / 3443

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Nelnet Inc
Nelnet Inc Nelnet Inc Valor: 1665235
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.52%USD 113.28
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-6.33%USD 24.56
Tilray Brands Inc
Tilray Brands Inc Tilray Brands Inc Valor: 42386407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.55%USD 1.80
Shattuck Labs Inc
Shattuck Labs Inc Shattuck Labs Inc Valor: 57260669
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%USD 3.66
Hims & Hers Health Inc
Hims & Hers Health Inc Hims & Hers Health Inc Valor: 59397181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%USD 16.31
Nano-X Imaging Ltd.
Nano-X Imaging Ltd. Nano-X Imaging Ltd. Valor: 56410599
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.73%USD 6.26
KK GNI Group
KK GNI Group KK GNI Group Valor: 3303570
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.38%JPY 2,493.00
Sandoz Group Ltd
Sandoz Group Ltd Sandoz Group Ltd Valor: 124359842
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.87%CHF 34.78
Stride Inc
Stride Inc Stride Inc Valor: 58406765
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.09%USD 81.92
Gyre Therapeutics Inc
Gyre Therapeutics Inc Gyre Therapeutics Inc Valor: 130270397
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.21%USD 13.87